ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.71 USD | +2.45% |
|
-0.65% | -46.63% |
| 04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
| 04-22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
| Sales 2024 * | 967M 77.43B | Sales 2025 * | 1.09B 87.16B | Capitalization | 2.75B 220B |
|---|---|---|---|---|---|
| Net income 2024 * | 110M 8.81B | Net income 2025 * | 221M 17.69B | EV / Sales 2024 * | 2.22 x |
| Net cash position 2024 * | 606M 48.55B | Net cash position 2025 * | 864M 69.13B | EV / Sales 2025 * | 1.74 x |
| P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
12.8
x | Employees | 598 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on ACADIA Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | +2.45% | ||
| 1 week | -0.65% | ||
| Current month | -9.63% | ||
| 1 month | -6.07% | ||
| 3 months | -37.97% | ||
| 6 months | -25.73% | ||
| Current year | -46.63% |
1 week
16.16
17.34
1 month
16.1618.63
Current year
16.1631.82
1 year
16.1633.99
3 years
12.2433.99
5 years
12.2458.72
10 years
12.2458.72
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14/07/14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 27/05/20 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 31/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 10/12/15 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 24/11/15 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14/07/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.73% | 1 M€ | -5.79% | - | |
| 1.24% | 16 M€ | -8.49% | ||
| 0.26% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 16.71 | +2.45% | 1,168,199 |
| 25/04/24 | 16.31 | -1.69% | 1,660,634 |
| 24/04/24 | 16.59 | -0.90% | 1,296,887 |
| 23/04/24 | 16.74 | -1.47% | 1,476,024 |
| 22/04/24 | 16.99 | +1.01% | 1,156,988 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
08/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.71
USD
Average target price
29.09
USD
Spread / Average Target
+74.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.63% | 2.75B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ACAD Stock
